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Abstract
Background: Gemcitabine (dFdC) is an active antitumour agent with radiosensitising properties,
shown both in preclinical and clinical studies. In the present study, the relation between
deoxycytidine kinase (dCK) activity and the radiosensitising effect of gemcitabine was investigated
in eight different human tumour cell lines.
Methods: Tumour cells were treated with dFdC (0–100 nM) for 24 h prior to radiotherapy (RT)
(γ-Co60, 0–6 Gy, room temperature). Cell survival was determined 7, 8, or 9 days after RT by the
sulforhodamine B test. dCK activity of the cells was determined by an enzyme activity assay.
Results: A clear concentration-dependent radiosensitising effect of dFdC was observed in all cell
lines. The degree of radiosensitisation was also cell line dependent and seemed to correlate with
the sensitivity of the cell line to the cytotoxic effect of dFdC. The dCK activity of our cell lines
varied considerably and differed up to three fold from 5 to 15 pmol/h/mg protein between the
tested cell lines. In this range dCK activity was only weakly related to radiosensitisation (correlation
coefficient 0.62, p = 0.11).
Conclusion:  Gemcitabine needs to be metabolised to the active nucleotide in order to
radiosensitise the cells. Since dFdCTP accumulation and incorporation into DNA are concentration
dependent, the degree of radiosensitisation seems to be related to the extent of dFdCTP
incorporated into DNA required to inhibit DNA repair. The activity of dCK does not seem to be
the most important factor, but is clearly a major factor. Other partners of the intracellular
metabolism of gemcitabine in relation to the cell cycle effects and DNA repair could be more
responsible for the radiosensitising effect than dCK activity.
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Background
Gemcitabine (2',2'-difluorodeoxycytidine, dFdC) is a syn-
thetic pyrimidine nucleoside analogue that has a structure
very similar to that of deoxycytidine and cytosine arabino-
side (Ara-C) [1]. In clinical use, gemcitabine is active
against a variety of solid tumours such as cancers of the
pancreas, lung, head and neck, bladder, breast, and ovary.
It is activated intracellularly by deoxycytidine kinase
(dCK), which adds a phosphate group to the 5' position
of the deoxyribose group. The diphosphate (dFdCDP)
and triphosphate (dFdCTP) forms of the drug play an
important role in the cytotoxic effect: dFdCDP is an inhib-
itor of ribonucleotide reductase, while dFdCTP is incorpo-
rated into DNA, both leading to the inhibition of DNA
synthesis. At the same time, gemcitabine has several self-
potentiation mechanisms that serve to increase intracellu-
lar levels of the active metabolite and increase cytotoxicity
[1,2]
In addition to its cytotoxic effect, gemcitabine is a potent
radiosensitiser when used in rodent and human tumour
cells, including pancreatic tumours, non-small cell lung
cancer, head and neck cancer, colorectal, breast, ovarian
and bladder cancer [3-14]. Gemcitabine can lead to a radi-
osensitising effect in both monolayer and spheroid gliob-
lastoma cultures [15]. Recent in vivo studies have
confirmed these observations and have shown significant
tumour growth delay with the combination of gemcitab-
ine and ionising radiation in animal models [4,5,16].
These results have prompted a variety of clinical trials
using gemcitabine as a radiosensitiser [17-31]. The exact
mechanism of radiosensitisation and most important fac-
tors are still not known yet. Although the effects of gem-
citabine on cell cycle redistribution and deoxynucleotide
triphosphate (dNTP) pools may contribute to, or even be
necessary for, gemcitabine-mediated radiosensitisation
[7,10,13], they do not ultimately determine whether or
not gemcitabine treatment is going to result in enhanced
radiosensitivity. For example, the role of dATP depletion
could not be confirmed in a study using cells with differ-
ent repair defects [32]. Wachters et al [33] have shown
that gemcitabine can sensitise cells to radiation by specific
interference with the homologous repair (HR) pathway.
Others have suggested that gemcitabine in combination
with radiotherapy is compromised by mismatch repair
(MMR), because recovery from gemcitabine treatment is
facilitated by, although not dependent on MMR profi-
ciency [34,35]
As a prodrug, gemcitabine requires intracellular phospho-
rylation to its active triphosphate form by dCK and to a
lesser extent by thymidine kinase (TK2) [36] to exhibit
biological activity. Acquired resistance to gemcitabine has
been associated with deficiency of dCK [37-40] It has been
shown that the expression of dCK at mRNA, protein and
activity level in cancer cell lines of different origin were
closely related and a correlation between the sensitivity to
gemcitabine and the activity of dCK was observed [41]. It
has also been shown that sensitivity to nucleoside ana-
logues could be restored by transfection of a wild type
dCK cDNA [42-44]. The critical role of dCK in gemcitab-
ine's radiosensitisation is not known. Previously a signifi-
cant relationship between dCK activity and sensitivity of
various xenografts to gemcitabine was described [41]
while accumulation of the triphosphate, dFdCTP, was
related to sensitivity to gemcitabine also [45]. Earlier data
with a gemcitabine resistant cell line, i.e. lacking dCK,
showed that these cells required a high concentration
(50–100 μM) of gemcitabine in order to get radiosensiti-
sation [46]. However, because radiosensitisation in vitro
increases with the drug concentration [12,47])., it could
be that the radiosensitising effect of gemcitabine also
depends on the rate of drug phosphorylation which in
turn depends on dCK activity [8] and drug concentration
[12,13,37,45,48]). Therefore, it has be hypothesized that
dCK activity could be an important factor for the radio-
sensitising effect of gemcitabine.
The purpose of the present study was to further substanti-
ate the role of dCK in gemcitabine's radiosensitisation.
Most studies investigating the radiosensitising effect of
gemcitabine are limited in cell types and only a few con-
centrations of gemcitabine are used. In this study, the
radiosensitising effect of gemcitabine was investigated in
eight human tumour cell lines, originating from different
tissues, using a range of gemcitabine concentrations.
Within that context, the role of dCK was further explored.
Methods
Chemicals and reagents
Dulbecco's Modified Eagle's Medium (DMEM), RPMI,
Medium 199, fetal calf serum and the medium supple-
ments L-glutamine and sodium pyruvate were all pur-
chased from Invitrogen (Merelbeke, Belgium).
Sulforhodamine B was obtained from ICN (Asse, Bel-
gium). Gemcitabine was purchased from Eli Lilly (Indian-
apolis, USA).
Cell lines
The cell lines used in this study were human tumour cells
differing in p53 status originating from different tissues:
ECV304 (mt-p53) a human epidermoid bladder cancer
cell line, H292 (wt-p53) a human mucoepidermoid lung
cancer cell line, A549 (wt-p53) a human squamous lung
cancer cell line, MCF-7 (wt-p53) a mammary carcinoma
cell line, HT-29 (mt-p53) a colon adenocarcinoma cell
line, Panc-1 (mt-p53) a human pancreatic epitheloid cell
line, CAL-27 (mt-p53) a human squamous cell carcinoma
cell line of the tongue and FaDu (mt-p53) a human squa-
mous cell carcinoma cell line of the pharynx. H292 andBMC Cancer 2006, 6:142 http://www.biomedcentral.com/1471-2407/6/142
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A549 were cultured in RPMI-1640 medium, supple-
mented with glutamine, sodium pyruvate and 10% fetal
calf serum. ECV304 was cultured in Medium-199 supple-
mented with 10% fetal calf serum. MCF-7, HT-29, CAL-27
and FaDu were cultured in DMEM medium, supple-
mented with glutamine and 10% fetal calf serum. Cul-
tures were maintained in exponential growth in a
humidified atmosphere at 37°C under 5% CO2/95% air.
Cell survival after treatment with gemcitabine and 
radiation
The sulforhodamine B (SRB) test is a suitable test system
for in vitro radiosensitivity testing, which in the presently
used cell lines has shown to be comparable in outcome
with the clonogenic assay, when cells are allowed to
undergo at least 6 doubling times after radiation treat-
ment [49]. Therefore, in our experiments, ECV304, H292,
A549, MCF-7, HT-29 and FaDu cells were incubated for 7
days, CAL-27 cells for 8 days and Panc-1 cells for 9 days
after radiation treatment, before determination of the sur-
vival by the SRB assay. Optimal seeding densities were
determined for each cell line to assure exponential growth
during the assay.
Cells were harvested from exponential phase cultures by
trypsinisation, counted and plated in 48-well plates. Fol-
lowing plating and a 24 h recovery period, cells were
treated with gemcitabine (0–100 nM) dissolved in phos-
phate buffered saline (PBS) during 24 h immediately fol-
lowed by radiation. PBS was added to control cells. Each
concentration was tested six times within the same exper-
iment. After irradiation at room temperature over a dose
range of 0–6 Gy, using a 60Co source (Alcyon, St Augusti-
nus hospital, Antwerp), cells were washed with drug free
medium. After 7, 8 or 9 days, the survival was determined
by the SRB assay. For determination of cell survival after
treatment with gemcitabine alone, the SRB assay was per-
formed 4 days after the start of treatment.
The SRB assay was performed according to the method of
Skehan and colleagues and Papazisis and colleagues, with
minor modifications [50,51] Culture medium was aspi-
rated prior to fixation of the cells by addition of 200 μl
10% cold trichloroacetic acid. After 1 h incubation at 4°C,
cells were washed 5 times with deionised water. Then the
cells were stained with 200 μl 0.1% SRB dissolved in 1%
acetic acid for at least 15 minutes and subsequently
washed 4 times with 1% acetic acid to remove unbound
stain. The plates were left to dry at room temperature and
bound protein stain was solubilised with 200 μl 10 mM
unbuffered TRIS base (tris(hydroxymethyl)aminometh-
ane) and transferred to 96 wells plates for reading the
optical density at 540 nm (Biorad 550 microplate reader,
Nazareth, Belgium).
dCK enzyme activity assays
To determine a possible correlation between dCK activity
and the radiosensitising effect of gemcitabine, cells were
harvested as described previously [41], and pellets were
stored at -80°C until analysis. 25.106 cells were used in
order to be able to measure enzyme activity in a linear
range for time and protein. dCK was determined essen-
tially as described previously [41]. To measure dCK selec-
tively and bypass TK2 mediated phosphorylation of
deoxycytidine, we used radiolabeled chlorodeoxyadenos-
ine ([3H]CdA) as the substrate [52], which is not activated
by TK2. Enzyme activities were expressed as nmol product
per h per mg protein (nmol/h/mg protein).
Statistical methods
The survivals were calculated by: mean optical density
(OD) of treated cells/mean OD of control cells × 100%.
The radiation survival curves were fitted according to the
linear-quadratic model: surviving fraction = exp(- αD –
βD2), using Winnonlin (Pharsight, USA).
The following parameters were calculated: ID50, the radi-
ation dose causing 50% growth inhibition and IC50, the
concentration gemcitabine causing 50% growth inhibi-
tion. The radiosensitising effect was represented by the
dose enhancement factor (DEF): ID50(-dFdC)/
ID50(+dFdC).
Unless otherwise indicated, all data are presented as the
mean ± standard deviation. All experiments were per-
formed at least three times. A two-sample t-test and one-
way ANOVA analysis was used to determine significance
between ID50 values and DEFs.
Radiosensitisation can be defined as a synergistic interac-
tion between gemcitabine and radiation. For the determi-
nation of synergism, the combination index (CI) was
calculated by the Chou-Talalay equation [47,53,54], using
CalcuSyn (Biosoft, USA, UK). The general equation for the
classic isobologram is given by:
where (Dx)1 and (Dx)2 in the denominators are the doses
(or concentrations) for D1 (gemcitabine) and D2 (radia-
tion) alone that give x% inhibition, whereas (D)1 and
(D)2 in the nominators are the doses of gemcitabine and
radiation in combination that also inhibit x% (i.e., isoef-
fect).
The (Dx)1 or (Dx)2 (for gemcitabine and radiation) can be
readily calculated from the median-effect equation of
Chou:
CI
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Where fa is the fraction affected and Dm is the median-
effect dose (ID50 or IC50) that is obtained from the anti-
log of the X-intercept of the median effect plot, X-log (D)
versus Y = log [fa/(1 - fa] or Dm = 10-(Y-intercept)/m, and m is
the slope of the median effect plot.
For conservative mutually nonexclusive isobolograms of
two agents, a third term,
is added. The third term is usually omitted, when the
mutually exclusive (α = 0) assumption or classic isobolo-
gram is used [53,55] Data in table 2 are based on the
assumption that α = 0.
A CI value between 0.9 and 1.1 indicates only additivity.
Moderate synergism is depicted by CI values between 0.7
and 0.9, synergism by CI values below 0.7.
Results
Radiosensitisation by gemcitabine
A clear concentration-dependent radiosensitising effect of
gemcitabine was observed in ECV304, FaDu, H292, A549,
CAL-27, Panc-1, MCF-7 and HT-29 cells (Figure 1 and 2).
ID50 values and DEFs for the different gemcitabine con-
centrations are summarised in Table 1.
The degree of radiosensitisation seemed to be cell line
dependent. For ECV304 and MCF-7 cells, the DEF after
treatment with 1 nM gemcitabine was 1.37, and 1.24,
respectively, while this concentration had no radiosensi-
tising effect in FaDu, H292, A549, CAL-27 and HT-29 cells
with DEF values around 1. In Panc-1 cells, much higher
concentrations (15–100 nM) of gemcitabine were
required to obtain a radiosensitising effect than in the
other cell lines (2–8 nM). Panc-1 cells were less sensitive
for the cytotoxic effect of gemcitabine alone as depicted by
the IC50 values in Table 1. The radiosensitising effect
seemed to correlate with the sensitivity of the cell line to
the cytotoxicity effects of gemcitabine (correlation coeffi-
cient for mean IC50 and mean DEF: -0.82, p = 0.013).
The CI analysis showed that after treatment during 24 h
with gemcitabine immediately before radiation treat-
ment, there is synergism in ECV304 with gemcitabine
concentrations of 2 nM or higher (CI ≤ 0.65), with con-
centrations of 4 nM or higher in A549 (CI ≤ 0.70), MCF-7
(CI ≤ 0.62) and FaDu (CI ≤ 0.50) and with concentrations
of 6 nM and higher in HT-29 cells (CI ≤ 0.39). Only mod-
erate synergism was observed with 6 nM or higher in
H292 (CI ≤ 0.88) and CAL-27 (CI ≤ 0.72). In Panc-1 cells,
concentrations of 7 nM and higher resulted in a moderate
to synergistic interaction (CI ≤ 0.79) (Figure 3).
dCK
Since our cell lines had a normal sensitivity range (nM
range) and had a DEF comparable to high and low values
in literature, we measured dCK activity in order to deter-
mine whether there would be relation between DEF and
dCK activity. Table 2 represents the dCK activity per cell
line. The dCK activity varied considerably from cell line to
cell line and differed up to three fold from 5 to 15 pmol/
h/mg protein between the tested cell lines. In this range
dCK activity was weakly related to DEF (correlation coef-
ficient = 0.62, p = 0.11) (Figure 4).
Discussion
This is the first study showing a clear concentration-
dependent radiosensitising effect of gemcitabine in a large
number of tumour cell lines, originating from different
tissues. In addition, we found that that there was a weak
positive correlation between dCK activity of these cells
and the DEF. Probably, more factors, including other part-
ners of the intracellular metabolism, cell cycle effects and
DNA repair play a role. This offers an explanation for the
variable results in the clinic.
In particular, we investigated the radiosensitising effect in
8 different cell lines, using various concentrations of gem-
citabine. Our data demonstrate that gemcitabine increases
the radiosensitivity of ECV304, H292, A549, MCF-7, HT-
29, CAL-27, Panc-1 and FaDu cells in vitro when the cells
are treated for 24 h immediately before radiation. The
enhancement is concentration dependent, with an
increasing DEF with higher concentrations of gemcitab-
ine.
Our DEFs are comparable to literature data from other cell
lines [6-13,46]). In most of these studies, the concentra-
tion of gemcitabine needed to achieve such a radiosensi-
tising effect, was higher than in our study. This seems to
be dependent on the sensitivity to the single agent gemcit-
abine of the cell lines studied since in gemcitabine-resist-
ant cell lines even μM concentrations of gemcitabine were
required [46]. In addition, this could also be due to differ-
ences in DNA repair between the cells. In our experiments,
the radiosensitising effect was cell line dependent; for
example, higher gemcitabine concentrations were needed
to induce radiosensitisation in Panc-1 cells (Table 1).
As mentioned gemcitabine is a prodrug that requires suc-
cessive intracellular phosphorylations into its active tri-
sphosphate form [56]. The enzyme dCK is required for the
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first phosphorylation step into dFdCMP, while non-spe-
cific kinases are responsible for the further phosphoryla-
tion steps. As it has been reported that the level of
enzymatic activity of dCK could have a profound influ-
ence on cellular resistance to gemcitabine cytotoxicity, the
present investigations were also designed to address the
relationship between gemcitabine's radiosensitisation
and the activity of dCK in various human tumour cell
lines. The range of dCK activity found in our cell lines, is
in agreement with the range found in other solid tumour
cell lines, but lower than in leukemic cell lines [57]. For
those cell lines investigated the extent of overall gemcitab-
ine phosphorylation to dFdCTP is related to the drug con-
centration and the activity of dCK [37,45,57]. However
other enzymes also contribute to the overall accumulation
and particularly the retention of dFdCTP, such as deoxycy-
tidine deaminase, pyrimidine 5'nucleotidase (5'NT),
aspecific nucleotidases and phosphatases, and incorpora-
tion into DNA and RNA.
Our results in 8 different human solid tumour cell lines
with a varying radiosensitising effect of gemcitabine did
not further validate the correlation between dCK activity
of the cells and the radiosensitising effect of gemcitabine.
Gregoire et al [58] reported a correlation between dCK
activity and gemcitabine's radiosensitisation. This correla-
tion held both for dCK mRNA expression and the protein
versus radiosensitisation [58]. Contrary to this, we could
only show a weak relation between the DEF and dCK
activity of eight different tumour cells. Possibly the range
of dCK activity in our panel was not large enough. In the
xenografts investigated for a relation between dCK activity
and gemcitabine's antitumor activity was larger [41].
Several hypotheses have been proposed to explain the
radiosensitisation potential of gemcitabine [59]. Of these,
most likely, cell cycle synchronization [7,60,61] and DNA
repair [32] play an important role in the radiosensitisa-
tion. In addition to the intracellular metabolism of gem-
citabine, for which dCK is a key factor, intrinsic variation
in the cellular response to the analogue after ionising radi-
ation is likely to also play a role in gemcitabine's radiosen-
sitisation. The relative importance of dCK activity among
these various parameters is, however, not clear. Possibly
the overall rate of initial gemcitabine phosphorylation is
also determined by the equilibrium between the activities
of dCK and the degrading enzyme, 5'NT, since the ratio
dCK/5'NT showed a better correlation with gemcitabine
Table 1: IC50, ID50 and DEFs of the different cell lines. Sensitivity of different cell lines for gemcitabine (indicated by IC50 values) and 
radiotherapy (indicated by ID50 values) alone and the radiosensitising effect of gemcitabine represented by dose enhancement factors 
(DEF). (mean ± S.D.).
Cell line IC50 (nM) ID50 (Gy) DEF 1 nM DEF 2 nM DEF 4 nM DEF 6 nM DEF 8 nM
ECV304 3.05 ± 0.49 3.37 ± 0.40 1.37 ± 0.06 2.41 ± 0.24 3.21 ± 0.25 3.64 ± 0.40 n.a.
FaDu 4.90 ± 0.46 3.09 ± 0.39 1.03 ± 0.04 1.22 ± 0.17 1.80 ± 0.26 2.37 ± 0.52 n.a.
H292 7.99 ± 0.77 4.00 ± 0.86 1.08 ± 0.10 1.23 ± 0.20 1.58 ± 0.22 2.07 ± 0.55 2.46 ± 0.82
A549 9.01 ± 0.89 4.51 ± 0.70 1.00 ± 0.04 1.21 ± 0.17 1.89 ± 0.51 2.39 ± 0.57 2.77 ± 0.26
CAL-27 8.92 ± 1.59 3.52 ± 0.88 1.06 ± 0.07 1.08 ± 0.04 1.49 ± 0.21 2.06 ± 0.06 2.51 ± 0.21
MCF-7 6.94 ± 2.03 4.96 ± 1.27 1.24 ± 0.06 1.45 ± 0.27 1.63 ± 0.13 2.55 ± 0.34 n.a.
HT-29 7.75 ± 1.61 5.64 ± 1.02 1.12 ± 0.21 1.30 ± 0.10 1.62 ± 0.04 2.39 ± 0.21 n.a.
Cell line IC50 (nM) ID50 (Gy) DEF 7 nM DEF 15 nM DEF 35 nM DEF 50 nM DEF 100 nM
Panc-1 77.8 ± 9.1 2.92 ± 0.35 1.20 ± 0.10 1.50 ± 0.19 1.55 ± 0.19 1.83 ± 0.20 1.56 ± 0.08
n.a. not analysed
Table 2: Deoxycytidine kinase (dCK) activity per cell line.
Cell line dCK activity (nmol/h/mg protein)
ECV304 15.29
FaDu 8.12
H292 10.51
A549 6.02
CAL-27 5.02
MCF-7 8.72
HT-29 7.11
Panc-1 8.89BMC Cancer 2006, 6:142 http://www.biomedcentral.com/1471-2407/6/142
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sensitivity than dCK activity alone [62]. Moreover, the
final mode of action of gemcitabine of producing a
"masked chain termination" after its incorporation into
DNA, favours that DNA repair plays an important role
with respect to sensitising the tumour cells to radiation.
Conclusion
Our study suggest that other partners of the intracellular
metabolism of gemcitabine in relation to cell cycle effects
and DNA repair could be more responsible for the radio-
sensitising effect of gemcitabine than dCK activity of the
cell.
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Radiation dose response curves Figure 1
Radiation dose response curves. Radiation dose responsecurves of ECV304, H292, A549, and FaDu cells after treatment with 
gemcitabine (dFdC) during 24 h immediately before radiation (RT) (survival ± S.D.)
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A c
Relationship between gemcitabine concentration and the combination index Figure 3
Relationship between gemcitabine concentration and the combination index. Relationship between the concentration of gemcitabine 
(dFdC) and the mean combination index (CI) for ECV304, FaDu, H292, A549, CAL-27, MCF-7 and HT-29 cells. The cells were 
treated during 24 h with gemcitabine immediately before radiotherapy (0–8 Gy). A CI value between 0.9 and 1.1 indicates only 
additivity. Moderate synergism is depicted by CI values between 0.7 and 0.9, synergism by CI values below 0.7.
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Radiation dose response curves Figure 2
Radiation dose response curves. Radiation dose responsecurves of HT-29, MCF-7, CAL-27 and Panc-1 cells after treatment with 
gemcitabine (dFdC) during 24 h immediately before radiation (RT) (survival ± S.D.)
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